Aphoenix bringing new drug targets to life
This article was originally published in Scrip
Executive Summary
The Japanese bioventure Aphoenix has developed "reverse targeting" technology which enables the discovery of binding proteins for small-molecule drugs with unknown mechanisms of action. The proprietary platform has resulted in several novel compounds which the private firm is now looking to partner.